None
Quote | DiaMedica Therapeutics Inc. (NASDAQ:DMAC)
Last: | $2.42 |
---|---|
Change Percent: | -1.99% |
Open: | $2.5599 |
Close: | $2.42 |
High: | $2.5599 |
Low: | $2.4131 |
Volume: | 5,228 |
Last Trade Date Time: | 04/23/2024 03:00:00 am |
News | DiaMedica Therapeutics Inc. (NASDAQ:DMAC)
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today announced the first patient being dosed in DiaMedica’s relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of...
2024-03-21 16:55:04 ET More on DiaMedica Therapeutics Seeking Alpha’s Quant Rating on DiaMedica Therapeutics Historical earnings data for DiaMedica Therapeutics Financial information for DiaMedica Therapeutics Read the full article on Seeking Alpha ...
Message Board Posts | DiaMedica Therapeutics Inc. (NASDAQ:DMAC)
Subject | By | Source | When |
---|---|---|---|
I don't understand the lack of interest. | Cincinnatus | investorshub | 11/04/2021 10:32:05 PM |
SEC Form 4s - Multiple informative buys from insiders. | TonyJoe1957 | investorshub | 08/17/2021 11:17:19 AM |
Very dead board, but I'll try once more. | Cincinnatus | investorshub | 05/12/2021 12:08:35 AM |
Secondary - 2.1M shares @ $4 | Plegee | investorshub | 02/11/2020 9:55:20 PM |
Provisional Approval?? | Cincinnatus | investorshub | 12/20/2019 4:44:16 PM |
News, Short Squeeze, Breakout and More Instantly...
DiaMedica Therapeutics Inc. Company Name:
DMAC Stock Symbol:
NASDAQ Market:
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today announced the first patient being dosed in DiaMedica’s relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of...
Conference Call and Webcast March 20 at 8:00 AM Eastern Time / 7:00 AM Central Time ReMEDy2 Clinical Site Activation Commenced in December 2023 Strengthened Management Team with Lorianne Masuoka, M.D., as Chief Medical Officer $53 Million Cash with Runway to 2026 ...
DiaMedica Presents the Protocol and Rationale for ReMEDy2, a Pivotal Trial in Patients Suffering Acute Ischemic Stroke Ineligible for tPA and/or Mechanical Thrombectomy DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developi...